Use of glycoprotein IIb/IIIa receptor antagonist in prosthetic valve thrombosis

By Caceres-Loriga F.   Santos-Gracia J.  

Platelets, Vol. 21, Iss. 7, 2010-11 ,pp. : 583-583

Informa Healthcare

Access to resources Recommend Favorite

Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist

By Seiffert Dietmar   Thomas Beth E.   Bradley Jodi D.   Munzer Deborah A.   Tchinnes Maureen A.   Kornhauser David M.   Cain Valerie A.   Hua Tsuhung A.   Feuerstein Giora Z.   Martin David E.   Stern Andrew M.  

Platelets, Vol. 14, Iss. 3, 2003-05 ,pp. : 179-187

Informa Healthcare

Access to resources Recommend Favorite

The IN VITRO AND IN VIVO PHARMACOLOGICAL PROFILES OF A PLATELET GLYCOPROTEIN IIb/IIIa ANTAGONIST, NSL-9403

By Katada J.   Takiguchi Y.   Muramatsu M.   Fujiyoshi T.   Uno I.  

Thrombosis Research, Vol. 88, Iss. 1, 1997-10 ,pp. : 27-40

Elsevier

Access to resources Recommend Favorite

The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary

By  

Current Cardiology Reviews, Vol. 4, Iss. 4, 2008-11 ,pp. : 293-299

Bentham Science Publishers

Access to resources Recommend Favorite

Antiplatelet and Antithrombotic Activity of RWJ-53308, A Novel Orally Active Glycoprotein IIb/IIIa Antagonist

By Damiano B.P.   Mitchell J.A.   Giardino E.   Corcoran T.   Haertlein B.J.   de Garavilla L.   Kauffman J.A.   Hoekstra  

Thrombosis Research, Vol. 104, Iss. 2, 2001-10 ,pp. : 113-126

Elsevier

Access to resources Recommend Favorite